Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/25
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business UpdatesGlobeNewsWire • 08/07/25
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesGlobeNewsWire • 07/21/25
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader MedicinesGlobeNewsWire • 07/03/25
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesGlobeNewsWire • 06/10/25
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a BetZacks Investment Research • 06/09/25
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/25
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/08/25
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business UpdatesGlobeNewsWire • 05/08/25
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast CancerGlobeNewsWire • 04/28/25
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top EstimatesZacks Investment Research • 03/20/25
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 ProgramsGlobeNewsWire • 03/20/25
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025GlobeNewsWire • 03/11/25
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/24/25
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short TermZacks Investment Research • 12/23/24
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast CancerGlobeNewsWire • 12/11/24
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersGlobeNewsWire • 12/11/24
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid TumorsGlobeNewsWire • 12/05/24
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?Zacks Investment Research • 12/02/24